Mean age (years±SD) | 63.9 ± 13.4 |
Gender (male/female ratio) | 8/4 |
Epistaxis (n/total) | 12/12 |
ESS at enrolment (mean ± SD) | 3.9 ± 2.8 |
Mucocutaneous teleangiectases other than endonasal (n/total) | 11/12 |
Anemia in the 3 months before enrolment (n/total) | 6/12 |
Mean Hb at enrolment (g/dl ± SD) | 11.4 ± 2.9 |
Blood transfusion(s) in the 3 months before enrolment (n/total) | 1/12 |
Family history of HHT (n/total) | 11/12 |
Pulmonary AVMs (n/screened) | 5/10 |
Hepatic AVMs (n/screened) | 1/10 |
Cerebral AVMs (n/screened) | 0/7 |
Gastrointestinal AVMs (n/screened) | 5/7 |
Previous gastrointestinal bleeding (n/total) | 5/12 |
Indication to AT | 12/12 |
Atrial Fibrillation (n/total) | 4/12 |
Venous thromboembolism (n/total) | 1/12 |
Previous stroke/transient ischemic attack (n/total) | 5/12 |
Previous myocardial infarction (n/total) | 2/12 |
Number of AT courses / number of patients | |
Anticoagulant therapy (n/total) | 5/12 |
Antiplatelet therapy (n/total) | 7/12 |
Mean duration of follow-up (months ± SD) | 6.5 ± 0.8 |
Mean duration of antiplatelet therapy courses (months±SD) | 6.9 ± 0.4 |
Mean duration of anticoagulant therapy courses (months±SD) | 6.2 ± 1.1 |